Related Experiment Videos
Mechanisms of muscarinic modulation of protein phosphorylation in intact ventricles
Abstract:
Muscarinic agonists inhibit cyclic AMP (cAMP)-induced phosphorylation of the cardiac protein phospholamban. The mechanism of this muscarinic inhibition of phosphorylation of phospholamban appears to occur at more than one level in the series of reactions comprising the adenylate cyclase, cAMP-dependent protein kinase system. Muscarinic agonists attenuate hormone and drug stimulation of cardiac adenylate cyclase. This results in reduced tissue levels of cAMP and diminished phosphorylation of cardiac proteins and consequent inhibition of biochemical and inotropic effects of drugs that act via cAMP. The mechanism of muscarinic inhibition of adenylate cyclase is only partially understood, but probably involves the inhibitory guanine nucleotide-binding regulatory protein. In addition to the inhibition of adenylate cyclase, muscarinic agonists appear to be able to inhibit the effects of cAMP. The mechanism for this second effect of muscarinic agonists is unknown.
Insights
Muscarinic agonists reduce cyclic AMP (cAMP) signaling in the heart by inhibiting adenylate cyclase and affecting cAMP
Area of Science:
- Cardiovascular Pharmacology
- Molecular Cardiology
- Signal Transduction
Background:
- Muscarinic agonists are known to modulate cardiac function.
- Cyclic AMP (cAMP) plays a crucial role in regulating cardiac contractility and biochemical processes.
- Phospholamban phosphorylation is a key event regulated by cAMP-dependent protein kinase.
Purpose of the Study:
- To elucidate the mechanisms by which muscarinic agonists inhibit cAMP-induced phospholamban phosphorylation in cardiac tissue.
- To investigate the impact of muscarinic agonists on the adenylate cyclase system and cAMP levels.
- To understand the multi-level inhibition of cAMP signaling by muscarinic agonists.
Main Methods:
- Investigated the effects of muscarinic agonists on cardiac adenylate cyclase activity.
- Assessed cAMP levels in response to hormonal and drug stimulation.
- Examined the phosphorylation status of phospholamban and other cardiac proteins.
Main Results:
- Muscarinic agonists attenuate hormone and drug-stimulated cardiac adenylate cyclase activity.
- This leads to reduced intracellular cAMP levels and diminished phospholamban phosphorylation.
- Muscarinic agonists inhibit cAMP-dependent protein kinase system at multiple levels, affecting biochemical and inotropic responses.
Conclusions:
- Muscarinic agonists exert a dual inhibitory effect on cAMP signaling in the heart.
- The inhibition involves attenuation of adenylate cyclase activity, potentially via inhibitory guanine nucleotide-binding proteins.
- Further research is needed to fully understand the mechanism of muscarinic inhibition of cAMP effects.